Search

The article focuses on the decision of the U.S. Supreme Court in the case Alice Corp. v. CLS Bank and impacts patent examiners and patent applicants in various technology areas. It mentions study compares patent applications in the control group with the patent applications in three technology areas-business methods, bioinformatics, and software. It also mentions eligible subject matter in patent law is a threshold requirement of patentability.

The article focuses on the role of courts in shaping patent law and policy in the U.S. Topics discussed include enactment of Patent Act of 1952 for governing patents in the country; guidance of the U.S. Patent and Trademark Office to help examiners and applicants who struggle with patent issues; and the U.S. Supreme Court cases Alice Corp. Pty. Ltd. v. CLS Bank Int'l and Mayo Collaborative Services v. Prometheus Laboratories on patentability.

The article discusses the U.S. Supreme Court case Alice Corporation Pty. Ltd. v. CLS Bank International which deals with the issue of patent eligibility.

The article reports the decision of the U.S. Supreme Court in the case 'Alice Corp. v. CLS Bank International' in which the court guided the administrative agencies such as U.S. Patent and Trademark Office over software's patent eligibility.

The article discusses the U.S. District Court for the Central District of California's ruling in the patent infringement case McRO Inc. v. Bandai Namco Games America Inc. (McRO), and it mentions how the court in the McRO case sought to clarify the patentable subject matter (patentability) test that was established by the U.S. Supreme Court in the 2014 patent litigation matter Alice Corp. Pty. Ltd. v. CLS Bank Int'l. McRO's patents for 3-D animation techniques and characters are also examined.

Imagine you invented a way to perform mathematical calculations all over the world simultaneously. Now, imagine that you cannot patent your invention because it was compared to, and found to contain, the same idea as an abacus. This scenario was the outcome of Alice Corp. v. CLS Bank International. In coming to its decision in Alice, the U.S. Supreme Court adopted a two-part test that it had previously utilized to analyze the patentability of laws of nature to determine whether the patent at issue met the subject matter patentability standards of § 101 of the Patent Act. Determining the claim contained an abstract idea, the Court then addressed whether the invention was a patentable application and found it was not because "generic" computer implementation did not add "significantly more" to the underlying idea. Since Alice, courts have invalidated a number of patents for failing to meet this criteria--arguably turning from the plain meaning of the Patent Act and congressional intent. Utilizing the Alice framework, courts have dismissed patent infringement claims in the pleading stages upon labeling them as abstract and citing reasoning as well as utilizing terminology that is more indicative of a § 102 or § 103 Patent Act analysis. While an argument can be made that proactively dismissing some claims in the pleading stages could reduce the prevalence of patent trolls and improve the efficiency of the patent process, this Note argues that the widespread proclivity of courts to invalidate patents under § 101 by utilizing language indicative of § 102 and § 103 analysis robs patent holders of the ability to have their claims analyzed under proper standards and injects subjective and uncertain criteria into the patent infringement analysis that could be avoided by implementing other analytical methods. As a remedy to the inclusion of § 102 and § 103 factors in the subject matter patentability analysis, this Note advocates that a substantial increase in speed or efficiency generated by an invention should be taken into account in determining if the invention adds "significantly more" to the idea. This would create a tangible bright-line test that would allow the claim to move forward and be analyzed under more suitable Patent Act sections. [ABSTRACT FROM AUTHOR]

The article examines the primary purpose of patent laws in the U.S. Topics discussed include the U.S. Supreme Court's decision in the case 'Alice Corp. v. CLS Bank International' in which the court held that the simple ideas are not patentable simply because they are done on a computer; impact of the decision on the non-practicing entities; and laws related to software and business method patents.

The article discusses whether computer software and business methods can be legally patented in the U.S. as of 2015, and it mentions the American Supreme Court's (USSC's) ruling in the case Alice Corp. v. CLS Bank International which deals with patent claims involving a computer-implemented escrow service. A two-part court test for determining whether legal claims are directed to a patent-ineligible concept is examined, along with USSC jurisprudence and patent prosecution in the country.

The article focuses on developments of patent law relevant to cyberspace with reference to several court cases in the U.S. Topics discussed include the U.S Supreme Court's decision in patent ineligibility case Alice Corp. Pty. Ltd. v. CLS Bank International that dealt with computer implementation of abstract ideas, the Federal Circuit's decision in case Limelight Networks, Inc. v. Akamai Technologies, Inc., that addressed infringement issues and case Nautilus, Inc. v. Biosig Instruments, Inc.

35 U.S.C. § 101 allows a patent for "any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof." Recently, the Supreme Court issued several key decisions affecting the doctrine of patentable subject matter under § 101. Starting with Bilski v. Kappos (2011), and continuing with Mayo Collaborative Services, Inc. v. Prometheus Laboratories (2012), Association for Molecular Pathology v. Myriad Genetics (2013) and, most recently, Alice Corporation Pty. Ltd. v. CLS Bank International (2014), every year has brought another major change to the way in which the Court assesses patentability. In Myriad, the Court directly addressed the patentability of isolated genetic material. Due to the underlying biological phenomena involved, this decision split genetic material into two groups. Large, complex animal, plant, and fungal genes remain patentable under some limited circumstances, while viral, bacterial, and simple eukaryotic genes are categorically unpatentable. The biotechnology industry evolved in an era in which gene patents were freely granted. As a result, legal and regulatory pathways have emerged that allow existing biotechnology products to be protected in many of the same ways as traditional pharmaceutical products. However, entirely new areas of biotechnology, those emerging in the shadow of Myriad, may be threatened by a deprivation of the incentives and protection that the patent system offers. This Note discusses one such new area of biotechnology, non-coding RNA therapeutics and diagnostics, and the ways in which the categorical exclusion of some genes threatens this promising area of innovation. In addressing this, I propose a re-ordering of the patentable subject matter analysis that would ameliorate many of these issues. [ABSTRACT FROM AUTHOR]